Why the study?
Does cardiovascular magnetic resonance imaging of fibrosis help differentiate physiological adaptation from pathological cardiomyopathy in athletes with left ventricular hypertrophy?
Does cardiovascular magnetic resonance imaging of fibrosis help differentiate physiological adaptation from pathological cardiomyopathy in athletes with left ventricular hypertrophy?
CMR imaging, particularly for myocardial fibrosis, is essential for distinguishing physiological athlete's heart from pathological cardiomyopathies in athletes with left ventricular hypertrophy.
CMR T1 mapping may aid fibrosis assessment in athletic LVH; leaves open prospective validation before routine screening use.
Long-term high-intensity physical activity is associated with morphological changes, termed as the 'athlete's heart'. The differentiation of physiological cardiac adaptive changes in response to high-level exercise from pathological changes consistent with an inherited cardiomyopathy is imperative. Cardiovascular magnetic resonance (CMR) imaging allows definition of abnormal processes occurring at the tissue level, including, importantly, myocardial fibrosis. It is therefore vital in accurately making this differentiation. In this review, we will review the role of CMR imaging of fibrosis, and detail CMR characterisation of myocardial fibrosis in various cardiomyopathies, and the implications of fibrosis. Additionally, we will outline advances in imaging fibrosis, in particular T1 mapping. Finally we will address the role of CMR in pre-participation screening.
No takes yet. Share an insight, caveat, or question.
Waterhouse et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: